Merck & Co (NY:MRK)

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax.

A Closer Look at 8 Analyst Recommendations For Merck & Co ↗

September 16, 2024

Via Benzinga

Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity

September 16, 2024

NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges ↗

September 16, 2024

NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1...

Via Benzinga

Where Will Merck Stock Be in 5 Years? ↗

September 14, 2024

This drugmaker faces a key test in the next several years.

The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.

Merck & Co Unusual Options Activity ↗

September 13, 2024

Via Benzinga

Merck Scores Two Key Victories With Keytruda In Women's Cancers ↗

September 15, 2024

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

September 15, 2024

Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma

September 15, 2024

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

September 14, 2024

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

September 14, 2024

Markets were mostly positive this week as benign inflation numbers did nothing to dampen expectations that the Federal Reserve will cut interest rates

MarketBeat Week in Review – 9/9 - 9/13

September 14, 2024

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

Topics Economy

September 14, 2024

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target ↗

September 13, 2024

Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028,...

Via Benzinga

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day ↗

September 13, 2024

The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.

The company is adding onto its success outperforming Merck's top drug in lung cancer patients.

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale ↗

September 12, 2024

Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.

Summit Therapeutics Surges on Trial Results: Time to Buy?

September 12, 2024

Merck to Participate in the Bank of America 2024 Global Healthcare Conference

September 11, 2024

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males

September 11, 2024

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.

Is Summit Therapeutics a Buy Now? ↗

September 10, 2024

The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.

Why Summit Therapeutics Rocketed Over 60% Today ↗

September 09, 2024

Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%.

Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 09, 2024

Via Benzinga

Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda ↗

September 09, 2024

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half ↗

September 09, 2024

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,...

Via Benzinga

Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

September 09, 2024

Via Benzinga

3 No-Brainer Dividend Stocks to Buy in September ↗

September 08, 2024

These stocks pay great dividends and could be long-term winners.

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

September 07, 2024

From Daiichi Sankyo

Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?

Is Merck Stock Undervalued After Its Colossal Earnings Growth?

September 07, 2024

Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock

September 06, 2024